Image_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo... by Fabian Aldunate (3935021)

“…In addition, we found evidence of an increase in antibody titers after transfusion, accompanied by a decrease in the levels of several cytokines responsible for cytokine storm.…”

Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”

MCP-1-deficiency decreased CD11c-expressing cells via impairing the production of ROS and decreased activation of PLCγ2, Akt, and ERK upon M-CSF stimulation in BMM. by Woon-Ki Kim (447798)

“…<p>BMMs from WT (open bar) and MCP-1-KO mice (oblique-lined bar) were incubated in the presence of M-CSF (30 ng/ml) with U73122 (10 µM), Akt inhibitor IV (0.3 µM), PD098059 (5 µM), DPI (50 nM), NAC (3 mM), or H₂O₂ (300 µM) for 4 d (A). *, <i>P</i><0.05; ***, <i>P</i><0.001 compared with vehicle-treated WT cells. …”

Inadequate riparian zone use directly decreases water quality of a low-order urban stream in southern Brazil by Enzo Luigi Crisigiovanni (8709570)

Fig 11 - by Qingling Bao (13570606)

Subjects:

Fig 12 - by Qingling Bao (13570606)

Subjects:

Fig 2 - by Qingling Bao (13570606)

Subjects:

Fig 9 - by Qingling Bao (13570606)

Subjects:

Fig 8 - by Qingling Bao (13570606)

Subjects:

Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy by Eric M. Davis (1733638)

“…After PAB, mice spent significantly more time in NREM sleep compared to the control group over a 24 hour period (53.5 ± 1.5% vs. 46.6 ± 1.4%; p < 0.01) and exhibited an inability to both cycle into REM sleep and decrease delta density across the light/sleep period. …”

Human adenovirus (HAdV) types HAdV-5 and HAdV-37 show decreased transduction efficiencies after treatment with cold atmospheric plasma (CAP). by Oskar Bunz (5900291)

Decrease in oxidative phosphorylation yield in presence of butyrate in perfused liver isolated from fed rats-0 by Jean-Louis Gallis (2926)

“…The reference (methylene-diphosphonic acid) is not shown (18.40 ppm) (number of scans = 148). B: 20 min after a perfusion of butyrate 3 mmol/L, effect (from the bottom to the top) of the simultaneous addition of IAA 0.5 mmol/L (2 min) and KCN 2.5 mmol/L (10 min) (number of scans = 60).…”

Decrease in oxidative phosphorylation yield in presence of butyrate in perfused liver isolated from fed rats-1 by Jean-Louis Gallis (2926)

“…The reference (methylene-diphosphonic acid) is not shown (18.40 ppm) (number of scans = 148). B: 20 min after a perfusion of butyrate 3 mmol/L, effect (from the bottom to the top) of the simultaneous addition of IAA 0.5 mmol/L (2 min) and KCN 2.5 mmol/L (10 min) (number of scans = 60).…”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial by ALINE TABORDA FLESCH (12724983)